Total trials
127
Active
25
Phase 3
3
Total enrollment
652,579
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Jieyu Chufan | — | — | — | — | — | 1 | |
| Jieyu Chufan Capsules simulant | — | — | — | — | — | 1 | |
| individualized vancomycin dosing based on the population pharmacokinetics (PK) model | — | — | — | — | — | 1 | |
| empirical vancomycin dosing | — | — | — | — | — | 1 | |
| Atorvastatin | — | — | — | — | — | 1 | |
| metformin | — | — | — | 7 | |||
| AKK | — | — | — | — | — | 1 | |
| Escitalopram | — | — | — | — | — | 2 | |
| Aripiprazole 5mg | — | — | — | — | — | 1 | |
| Routine Pharmacological Treatment | — | — | — | — | — | 1 | |
| 160 units nasal insulin spray | — | — | — | — | — | 1 |
Next readouts
- 2024-12
- 2024-12-31
- 2026-04-08
- 2026-12-20
- 2026-12-31
- 2027-09-01
- 2027-12-31
Top conditions
- Schizophrenia27
- Bipolar Disorder6
- Depression5
- Major Depressive Disorder4
- Aortic Dissection3
- Major Depressive Disorder (MDD)3
- Parkinson Disease3
- Obsessive-Compulsive Disorder2
Frequently asked questions about Central South University
- How many clinical trials does Central South University have on ClinicalTrials.gov?
- Central South University is listed as the lead sponsor on 127 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Central South University's trials are in Phase 3?
- 3 of Central South University's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does Central South University focus on?
- Central South University's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Bipolar Disorder, Depression, Major Depressive Disorder, Aortic Dissection.
- When are Central South University's next clinical trial readouts?
- Central South University has 7 upcoming primary-completion readouts tracked here; the soonest is “Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model”, expected around 2024-12.